Biotech-in-a-box™️ has been saved
Supporting Biotechs on the Journey to Market
Product Launch Planning
The necessity of small to medium-sized life science companies in the response to the COVID-19 crisis has put the biotech industry in a well-deserved spotlight. Tasked with the development of novel diagnostics, vaccines and roll out of the world’s fastest ever clinical trials, the pandemic has created a paradigm shift for the biotech market. Investment has flowed inwardly to support this innovative landscape, with the UK biotech market alone reporting 60% growth in investment from previous years. Strong European foundations for biotechs further support this trend and provide opportunities for companies to expand geographically to capture wider patient audiences.
However, small to medium-sized life science companies still face significant challenges on their journeys to market. Successfully navigating the Biotech life cycle includes securing IP, managing R&D, raising funds (including IPO), launching product/portfolio and expanding operations geographically. Next-generation Biotechs (including cell and gene therapies) face further challenges from the added layer of complexity that surrounds how companies must address novel patient, product and payment journeys
What is Biotech-in-a-box™?
Deloitte’s network of Life-science Catalyst and Tech hubs exist to support the life-science ecosystem. At its centre, Biotech-in-a-box™️ provides a ‘one-stop shop’ to support the growth of small to mid-cap life sciences companies along their journey to market by leveraging Deloitte’s whole portfolio of capabilities and offerings. Our global footprint of over 9,000 practitioners in over 90 countries includes work with leading companies across the life sciences industry spanning across a diverse range of cross-functional capabilities (including Strategy, Research, Commercialisation, Tax, Finance, Legal, Supply Chain, Regulatory, Technology and Human Resource). We have expertise in delivery (the design, build and run of research/commercial operations), partnership (assessing partnership options, finding the right partner, and delivering the right risk/reward relationship), launch of products or services (supported >100 launch-related efforts in the last 12 months), and are skilled in end-to-end next generation capabilities to support the unique needs of small and mid-cap companies.
Across a biotech’s journey to market, Biotech-in-a-box continues to innovate bespoke offerings that leverage Deloitte’s cross-service skill sets and capabilities to address the individual needs of biotechs at different stages of their development cycle.
To ensure successful build and scale-up of the enterprise, defining the capability requirements for successful launch is key. We support biotech and medtech companies in understanding what maturity level is optimal, which capabilities need to be fully operational and by when, how to overcome key challenges in acquiring specific capabilities and which to build in-house vs. outsource, all based on their launch strategies, priorities and goals. We would like to partner with biotech and medtech companies and de-risk the scaling-up journey. The level of Deloitte’s involvement as a strategic partner can take a variety of forms, ranging from Deloitte being on-site and leading the execution to full autonomy for the partners, with Deloitte providing assistance as and when necessary as a strategic advisor.
What is required to scale successfully?
Biotech’s presence in overall biopharma research and development has been increasing in recent years with a leading role in developing COVID-19 vaccines or treatments today.
Life Sciences and Health Care Predictions 2022
Our latest report looks at the current state of R&D returns for 15 leading biopharma companies, the impact of the pandemic on R&D pipelines during 2021 and how this has expedited the adoption of digital solutions and impacted the IRR.